Valeant Picks New CFO From Zoetis in Ongoing Company Shakeup

Updated on
  • Paul Herendeen replaces Rob Rosiello as Valeant seeks comeback
  • Drugmaker’s shares rise 9.2 percent on news of new CFO

Valeant Pharmaceuticals International Inc. chose Paul Herendeen, a former executive at Warner Chilcott Plc and veterinary drugmaker Zoetis Inc., as its new chief financial officer in an ongoing leadership shakeup sparked by an accounting scandal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.